Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 659Carcinoma, Renal Cell 385Carcinoma, Non-Small-Cell Lung 243Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 192Neoplasms 178Colorectal Neoplasms 161Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 127Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 114Squamous Cell Carcinoma of Head and Neck 107Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 88Carcinoma, Hepatocellular 80Triple Negative Breast Neoplasms 76Esophageal Neoplasms 76Endometrial Neoplasms 75Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 55Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Hormone Refractory Prostate Cancer × Genitourinary × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡